Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2012 4
2013 3
2014 5
2015 5
2016 6
2017 4
2018 5
2019 6
2020 10
2021 7
2022 5
2023 5
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Digital Ischemia as a Rare Manifestation of C3 Glomerulopathy Associated With Monoclonal Gammopathy.
Baber A, Legendre P, Chauvet S, Karras A, Deshayes S, Huart A, Vignon M, Dessaix K, Hervier B, Legallicier B, Silva NM, Frémeaux-Bacchi V, Terrier B. Baber A, et al. Among authors: huart a. Kidney Int Rep. 2023 Dec 13;9(3):712-716. doi: 10.1016/j.ekir.2023.12.001. eCollection 2024 Mar. Kidney Int Rep. 2023. PMID: 38481513 Free PMC article. No abstract available.
Towards etiological treatments in cardiomyopathies.
Lairez O, Fournier P, Itier R, Bachelet B, Huart A, Cariou E. Lairez O, et al. Among authors: huart a. Presse Med. 2024 Mar;53(1):104223. doi: 10.1016/j.lpm.2024.104223. Epub 2024 Feb 2. Presse Med. 2024. PMID: 38309622 Free article. Review.
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.
Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, Huart A, Javaugue V, Pascal L, Royer B, Talbot A, Gounot R, Hegenbart U, Schonland S, Karlin L, Harel S, Kastritis E, Bridoux F, Jaccard A, Arnulf B. Forgeard N, et al. Among authors: huart a. Blood. 2024 Feb 22;143(8):734-737. doi: 10.1182/blood.2023022937. Blood. 2024. PMID: 38096365 No abstract available.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Delestre F, Charles P, Karras A, Pagnoux C, Néel A, Cohen P, Aumaître O, Faguer S, Gobert P, Maurier F, Samson M, Godmer P, Bonnotte B, Cottin V, Hanrotel-Saliou C, Le Gallou T, Carron PL, Desmurs-Clavel H, Direz G, Jourde-Chiche N, Lifermann F, Martin-Silva N, Pugnet G, Quéméneur T, Matignon M, Benhamou Y, Daugas E, Lazaro E, Limal N, Ducret M, Huart A, Viallard JF, Hachulla E, Perrodeau E, Puechal X, Guillevin L, Porcher R, Terrier B; French Vasculitis Study Group (FVSG). Delestre F, et al. Among authors: huart a. Ann Rheum Dis. 2024 Jan 11;83(2):233-241. doi: 10.1136/ard-2023-224623. Ann Rheum Dis. 2024. PMID: 37918894
Birtamimab: a new amyloidosis treatment?
Huart A. Huart A. Blood. 2023 Oct 5;142(14):1178-1180. doi: 10.1182/blood.2023021311. Blood. 2023. PMID: 37796521 No abstract available.
Membranous Nephropathy After Exposure to Immune Checkpoint Inhibitors.
Benyahia R, Lazareth H, Flahault A, Brglez V, Seitz-Polski B, El Fil S, Mazières J, Ribes D, Huart A, Colombat M, Karras A, Belliere J. Benyahia R, et al. Among authors: huart a. Kidney Int Rep. 2023 Jun 8;8(9):1892-1898. doi: 10.1016/j.ekir.2023.06.001. eCollection 2023 Sep. Kidney Int Rep. 2023. PMID: 37705909 Free PMC article. No abstract available.
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Talbot A, Bobin A, Tabone L, Lambert J, Boccaccio C, Deal C, Petillon MO, Allangba O, Agape P, Arnautou P, Belkhir R, Cailleres S, Chaoui D, Chrétien ML, Decaux O, Schulmann S, Frenzel L, Gastaud L, Huart A, Hulin C, Karlin L, Laribi K, Le Calloch R, Lenain P, Macro M, Manier S, Montes L, Moreau S, Moreau P, Morel V, Norwood J, Piocelle FO, Perrot A, Pica GM, Rey P, Schmitt A, Stoppa AM, Tiab M, Touzeau C, Vidal V, Vignon M, Vincent L, Van De Wyngaert Z, Zarnitsky C, Kerbouche N, Paka P, Leleu X, Arnulf B, Avet-Loiseau H, Du Myélome IIF. Talbot A, et al. Among authors: huart a. Haematologica. 2023 Oct 1;108(10):2774-2782. doi: 10.3324/haematol.2022.281772. Haematologica. 2023. PMID: 37078253 Free PMC article.
64 results